LuPIN abstract, page-18

It's a strange argument you make @vrs37 If they had conclusively proved the effect, the market cap would rightly be in the many billions. But you're right. They haven't conclusively proved it, and so it's not.

I don't think the average HC punter will be hoodwinked by some (debatable) overenthusiasm in an announcement, as you imply. In any case, not in big enough magnitude to impact the share price.

There's a growing body of evidence, but it's still a small cap biotech with all the risks and pitfalls inherent in that. Don't risk anything you can't afford to lose; there will undoubtedly be more bumps along the way, but a stock with a risk/reward ratio like this comes along very rarely.